文献速递妇科

一种经济有效的、基于机器学习的子宫内膜癌患者新型统一风险分类评分(NU-CATS)

A cost-effective, machine learning-based new unified risk-classification score (NU-CATS) for patients with endometrial cancer.
PubMed 文献 · Gynecol Oncol · 2023-06-17

研究利用癌症基因组图谱子宫体子宫内膜癌(596例)、纪念斯隆凯特琳转移事件与趋向性(1315例)及美国癌症研究协会项目基因组学证据肿瘤信息交换(4561例)数据集,构建基于机器学习的人工神经网络,纳入年龄、种族、组织学、错配修复状态和TP53突变状态,形成NU-CATS评分,在预测腹腔内进展方面准确率达75%,并显示NU-CATS评分越高,盆腔或腹主动脉旁淋巴结阳性及远处转移风险越高。

要点

  • NU-CATS评分纳入年龄、种族、组织学、错配修复状态和TP53突变状态,预测腹腔内进展准确率为75%。
  • NU-CATS评分越高,盆腔或腹主动脉旁淋巴结阳性及远处转移风险越高。
  • 在黑人子宫内膜癌患者中,NU-CATS在估计FIGO I/II期疾病进展和生存风险方面优于Leiden/TransPORTEC模型。

核心结论

  • NU-CATS是一种基于机器学习、经济有效的算法,整合子宫内膜癌多种临床病理和分子变量,对淋巴结受累、远处转移、疾病进展和总生存提供更优的预后预测。

研究设计与样本

  • 研究使用癌症基因组图谱-子宫体子宫内膜癌(n=596)、纪念斯隆凯特琳-转移事件与趋向性(n=1315)和美国癌症研究协会项目基因组学证据肿瘤信息交换(n=4561)数据集识别遗传改变和临床病理特征,并测试Keras、Pytorch和Scikit Learn软件包构建人工神经网络,输出二分类结果为腹腔内转移进展(‘1’)与非转移(‘0’)。

主要发现

  • 调整TP53或POLE突变状态后,黑人子宫内膜癌患者预后比白人患者差。
  • 超过75%的黑人患者携带TP53突变,而白人患者约为40%。
  • 年龄较大与TP53突变、高风险组织学和远处转移的可能性增加相关。
  • 对于70岁以上患者,91%的黑人和60%的白人子宫内膜癌患者携带TP53突变。
  • 基于机器学习的NU-CATS评分在预测腹腔内进展方面准确率为75%,且NU-CATS评分越高,盆腔或腹主动脉旁淋巴结阳性及远处转移风险越高;在黑人子宫内膜癌患者中,NU-CATS在估计FIGO I/II期疾病进展和生存风险方面优于Leiden/TransPORTEC模型。

关键数值与推荐

  • NU-CATS评分纳入年龄、种族、组织学、错配修复状态和TP53突变状态。
  • NU-CATS预测腹腔内进展的准确率为75%。
  • 黑人患者中超过75%携带TP53突变,白人患者中约40%携带TP53突变。
  • 70岁以上患者中,黑人91%、白人60%携带TP53突变。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Treatment for endometrial cancer (EC) is increasingly guided by molecular risk classifications. Here, we aimed at using machine learning (ML) to incorporate clinical and molecular risk factors to optimize risk assessment. METHODS: The Cancer Genome Atlas-Uterine Corpus Endometrial Carcinoma (n = 596), Memorial Sloan Kettering-Metastatic Events and Tropisms (n = 1315) and the American Association for Cancer Research Project Genomics Evidence Neoplasia Information Exchange (n = 4561) datasets were used to identify genetic alterations and clinicopathological features. Software packages including Keras, Pytorch, and Scikit Learn were tested to build artificial neural networks (ANNs) with a binary output as either intra-abdominal metastatic progression ('1') vs. non-metastatic ('0'). RESULTS: Black patients with EC have worse prognosis than White patients, adjusting for TP53 or POLE mutation status. Over 75% of Black patients carry TP53 mutations as compared to approximately 40% of White patients. Older age is associated with an increasing likelihood of TP53 mutation, high risk histology, and distant metastasis. For patients above age 70, 91% of Black and 60% of White EC patients carry TP53 mutations. A ML-based New Unified classifiCATion Score (NU-CATS) that incorporates age, race, histology, mismatch repair status, and TP53 mutation status showed 75% accuracy in prognosticating intra-abdominal progression. A higher NU-CATS is associated with an increasing risk of having positive pelvic or para-aortic lymph nodes and distant metastasis. NU-CATS was shown to outperform Leiden/TransPORTEC model for estimating risk of FIGO Stage I/II disease progression and survival in Black EC patients. CONCLUSION: The NU-CATS, a ML-based, cost-effective algorithm, incorporates diverse clinicopathologic and molecular variables of EC and yields superior prognostication of the risk of nodal involvement, distant metastasis, disease progression, and overall survival.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Zheng S, Wu Y, Donnelly ED, et al. A cost-effective, machine learning-based new unified risk-classification score (NU-CATS) for patients with endometrial cancer. Gynecol Oncol. 2023. PMID: 37336081. doi:10.1016/j.ygyno.2023.06.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。